Outcomes of Autologous Hematopoietic Cell Transplantation Compared With Chemotherapy Consolidation Alone for Non–High-Risk Acute Myeloid Leukemia in First Complete Remission in a Minority-Rich Inner-City Cohort With Limited Access to Allografts

Transplantation Referral Patterns for Patients with Newly Diagnosed Higher-Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia at Academic and Community Sites in the Connect® Myeloid Disease Registry: Potential Barriers to Care

“…Allogeneic HCT is an expensive procedure, at a cost of USD $544,178, compared with $280,788 for chemotherapy in patients with AML. Additionally, such factors as a lack of family or social support and smaller numbers of ethnic minority donors in registries can affect access [ 26 ]. Data from several studies suggest that such socioeconomic factors act as nonclinical barriers to transplantation [ 26 – 28 ].…”